pocenbrodib
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 7, 2025 (NCT06785636)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CREB-binding proteinINHIBITOR
CREBBP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N1c2ccc3c(nc([C@H](O)c4cc(F)ccc4OC)n3[C@@H]3CCC[C@@H](C(=O)O)C3)c2CC[C@@H]1C- Mol. weight
- 525.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314476 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06785636 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2025 | Duke University, Pathos AI, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Pathos AI, Inc. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1